Advertisement
Thyroid| Volume 171, ISSUE 1, P140-146, January 2022

Insurance type is associated with appropriate use of surgical and adjuvant care for differentiated thyroid carcinoma

Published:September 30, 2021DOI:https://doi.org/10.1016/j.surg.2021.07.038

      Abstract

      Background

      We aimed to characterize the association between differentiated thyroid cancer (DTC) patient insurance status and appropriateness of therapy (AOT) regarding extent of thyroidectomy and radioactive iodine (RAI) treatment.

      Methods

      The National Cancer Database was queried for DTC patients diagnosed between 2010 and 2016. Adjusted odds ratios (AOR) for AOT, as defined by the American Thyroid Association guidelines, and hazard ratios (HR) for overall survival (OS) were calculated. A difference-in-differences (DD) analysis examined the association of Medicaid expansion with outcomes for low-income patients aged <65.

      Results

      A total of 224,500 patients were included. Medicaid and uninsured patients were at increased risk of undergoing inappropriate therapy, including inappropriate lobectomy (Medicaid 1.36, 95% confidence interval [CI]: 1.21–1.54; uninsured 1.30, 95% CI: 1.05–1.60), and under-treatment with RAI (Medicaid 1.20, 95% CI: 1.14–1.26; uninsured 1.44, 95% CI: 1.33–1.55). Inappropriate lobectomy (HR 2.0, 95% CI: 1.7–2.3, P < .001) and under-treatment with RAI (HR 2.3, 95% CI: 2.2–2.5, P < .001) were independently associated with decreased survival, while appropriate surgical resection (HR 0.3, 95% CI: 0.3–0.3, P < .001) was associated with improved odds of survival; the model controlled for all relevant clinico-pathologic variables. No difference in AOT was observed in Medicaid expansion versus non-expansion states with respect to surgery or adjuvant RAI therapy.

      Conclusion

      Medicaid and uninsured patients are at significantly increased odds of receiving inappropriate treatment for DTC; both groups are at a survival disadvantage compared with Medicare and those privately insured.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Howlader N.
        • Noone A.M.
        • Krapcho M.
        • et al.
        SEER cancer statistics review, 1975–2017.
        https://seer.cancer.gov/csr/1975_2017/
        Date accessed: January 20, 2021
        • Sherman S.I.
        Thyroid carcinoma.
        Lancet. 2003; 361: 501-511
        • Haugen B.R.
        • Alexander E.K.
        • Bible K.C.
        • et al.
        2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.
        Thyroid. 2016; 26: 1-133
        • Megwalu U.C.
        • Ma Y.
        • Hernandez-Boussard T.
        • Divi V.
        • Gomez S.L.
        The impact of hospital quality on thyroid cancer survival.
        Otolaryngol Head Neck Surg. 2020; 162: 269-276
        • Shah S.A.
        • Adam M.A.
        • Thomas S.M.
        • et al.
        Racial disparities in differentiated thyroid cancer: have we bridged the gap?.
        Thyroid. 2017; 27 (762–72)
        • Ullmann T.M.
        • Gray K.D.
        • Limberg J.
        • et al.
        Insurance status is associated with extent of treatment for patients with papillary thyroid carcinoma.
        Thyroid. 2019; 29: 1784-1791
        • Limberg J.
        • Stefanova D.
        • Thiesmeyer J.W.
        • et al.
        Association of medicaid expansion of the Affordable Care Act with the stage at diagnosis andtreatment of papillary thyroid cancer: a difference-in-differences analysis.
        Am J Surg. 2021; 222: 562-569
        • Schuman A.D.
        • Spector M.E.
        • Jaffe C.A.
        • et al.
        Changes in diagnosis of thyroid cancer among medicaid beneficiaries following medicaid expansion.
        JAMA Surg. 2020; 155: 1080-1081
        • American College of Surgeons, American Cancer Society
        National Cancer Database.
        • Ahmadi S.
        • Stang M.
        • Jiang X.S.
        • Sosa J.A.
        Hürthle cell carcinoma: current perspectives.
        Onco Targets Ther. 2016; 9: 6873-6884
      1. Medicaid. Enrollment report.
      2. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.
        Thyroid. 2009; 19: 1167-1214
        • Shaha A.R.
        • Shah J.P.
        • Loree T.R.
        Low-risk differentiated thyroid cancer: the need for selective treatment.
        Ann Surg Oncol. 1997; 4: 328-333
        • Adam M.A.
        • Pura J.
        • Gu L.
        • et al.
        Extent of surgery for papillary thyroid cancer is not associated with survival: an analysis of 61,775 patients.
        Ann Surg. 2014; 260 (discussion 605–7): 601-605
        • Agarwal P.
        • Jones E.A.
        • Devaiah A.K.
        Education and insurance status: Impact on treatment and survival of sinonasal cancer patients.
        Laryngoscope. 2020; 130: 649-658
        • Saraswathula A.
        • Megwalu U.C.
        Insurance status and survival of patients with salivary gland cancer.
        Otolaryngol Head Neck Surg. 2018; 159: 998-1005
        • Vernon J.A.
        • Trujillo A.
        • Rosenbaum S.
        • DeBuono B.
        Low health literacy: implications for national health care policy.
        (Accessed January 22, 2021)
        • Brewer N.T.
        • Tzeng J.P.
        • Lillie S.E.
        • Edwards A.S.
        • Peppercorn J.M.
        • Rimer B.K.
        Health literacy and cancer risk perception: implications for genomic risk communication.
        Med Decis Making. 2009; 29: 157-166
        • Koay K.
        • Schofield P.
        • Jefford M.
        Importance of health literacy in oncology.
        Asia Pac J Clin Oncol. 2012; 8: 14-23
      3. Ohri N, Rapkin BD, Guha D, et al. Predictors of radiation therapy noncompliance in an urban academic cancer center. Int J Radiat Oncol Biol Phys. 201591:232–8.

        • Jakob D.A.
        • Riss P.
        • Scheuba C.
        • et al.
        Association of surgical volume and quality management in thyroid surgery: a two-nation multicenter study.
        World J Surg. 2019; 43: 2218-2227
        • Lam M.B.
        • Phelan J.
        • Orav E.J.
        • Jha A.K.
        • Keating N.L.
        Medicaid expansion and mortality among patients with breast, lung, and colorectal cancer.
        JAMA Netw Open. 2020; 3e2024366